Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II double-blind placebo-controlled study of CYT005-AllQbG10 in adults with house dust mite allergic rhinoconjunctivitis
2007-003454-29Phase 2Completed
- Sponsor
- Cytos Biotechnology AG
- Start
- Jul 2007
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CYT005-AllQbG10, CYT003-QbG10, house dust mite allergen in allergic rhinoconjunctivitis (ARC), sponsored by Cytos Biotechnology AG. Started Jul 2007; status: completed.
02
Drugs
CYT005-AllQbG10CYT003-QbG10house dust mite allergen
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2007-003454-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003454-29.